Indian J Ophthalmol. 2007 Nov-Dec;55(6):441-3.

The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration.

Source

Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi - 110 029, India. rajvardhanazad@hotmail.com

Abstract

Age-related macular degeneration (ARMD) is the most common cause for visual impairment in the elderly in western countries. Recently several anti-vascular endothelial growth factor (VEGF) drugs like pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin) are available for use in the management of wet ARMD. A major limitation of these drugs is that they require multiple intravitreal injections, every 4 to 6 weeks interval for a period of 2 years. Moreover, most of these drugs are too expensive for the general masses to afford in developing nations. Avastin, though used "off-label", offers a comparable result at affordable cost, however, long term results are awaited. The drug industry should review the entire pricing policy of these drugs in developing countries like India, and develop affordable alternative compounds. The article reviews the economic burden and affordability issues of these Anti-VEGF drugs in ARMD.

PMID:: 17951901; [PubMed - indexed for MEDLINE]
PMCID:: PMC2636001

Free PMC Article

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Icon for Medknow Publications and Media Pvt Ltd

Save items

Related citations in PubMed

Review A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). [Indian J Ophthalmol. 2007]
Review A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
Nagpal M, Nagpal K, Nagpal PN. Indian J Ophthalmol. 2007 Nov-Dec; 55(6):437-9.
[The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes]. [Cesk Slov Oftalmol. 2007]
[The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
Karel I. Cesk Slov Oftalmol. 2007 Sep; 63(5):311-9.
Review The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. [Indian J Ophthalmol. 2007]
Review The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice.
Hussain N, Ghanekar Y, Kaur I. Indian J Ophthalmol. 2007 Nov-Dec; 55(6):445-50.
[Lucentis versus Avastin--is there a light at the end of the tunnel for age-related macular degeneration patients?]. [Harefuah. 2008]
[Lucentis versus Avastin--is there a light at the end of the tunnel for age-related macular degeneration patients?].
Waisbourd M, Leibovitch I, Loewenstein A, Yassur Y. Harefuah. 2008 Jul; 147(7):605-6, 662.
Review Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. [Drugs Aging. 2007]
Review Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I. Drugs Aging. 2007; 24(8):643-62.

See reviews... See all...

Cited by 1 PubMed Central article

Off with the label and on the Avastin bandwagon: why now and how far? [Indian J Ophthalmol. 2009]
Off with the label and on the Avastin bandwagon: why now and how far?
Santhan Gopal KS. Indian J Ophthalmol. 2009 Jul-Aug; 57(4):253-6.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

The economic implications of the use of anti-vascular endothelial growth factor ...
The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration.
Indian J Ophthalmol. 2007 Nov-Dec ;55(6):441-3.

PubMed
The endothelial vesicle system in cryofixed frog mesenteric capillaries analysed...
The endothelial vesicle system in cryofixed frog mesenteric capillaries analysed by ultrathin serial sectioning.
J Electron Microsc Tech. 1991 Nov ;19(3):291-304.

PubMed
IEM: an algorithm for iterative enhancement of motifs using comparative genomics...
IEM: an algorithm for iterative enhancement of motifs using comparative genomics data.
Comput Syst Bioinformatics Conf. 2007 ;6:227-35.

PubMed
Clustering of main orthologs for multiple genomes.
Clustering of main orthologs for multiple genomes.
Comput Syst Bioinformatics Conf. 2007 ;6:195-201.

PubMed
Prediction of transcription start sites based on feature selection using AMOSA.
Prediction of transcription start sites based on feature selection using AMOSA.
Comput Syst Bioinformatics Conf. 2007 ;6:183-93.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: